A Case of Extramedullary Progression Despite of Serologic Improvement in a Patient Treated with Thalidomide for Multiple Myeloma.
10.5045/kjh.2005.40.3.188
- Author:
Young Jin YUH
1
;
Hyun Su KIM
;
Young Jung PARK
;
Heung Sik UM
;
Sang Bong CHOI
;
Ban Suck LEE
;
Sung Rok KIM
;
Tae Hui HAN
Author Information
1. Department of Internal Medicine, Sanggyepaik Hospital, Inje University College of Medicine, Seoul, Korea. yjyuh@sanggyepaik.ac.kr
- Publication Type:Case Report
- Keywords:
Thalidomide;
Multiple myeloma;
Extramedullary plasmacytoma
- MeSH:
Humans;
Multiple Myeloma*;
Plasmacytoma;
Thalidomide*;
Tumor Burden
- From:Korean Journal of Hematology
2005;40(3):188-191
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Thalidomide is an anti-angiogenic agent widely used in patients with multiple myeloma. The response to therapy is commonly monitored using serum and/or urine M protein, as these are known to reflect the tumor burden. Although extramedullary plasmacytomas are tissues with high neovascularization, it has been suggested in some reports that the response to thalidomide in these patients may be inferior, despite changes in the serum M protein level. Herein, we report the case of a patient who newly developed hepatosplenic extramedullary plasmacytoma, despite reduction in the serum M protein level following thalidomide treatment.
